NRF-2 and nonalcoholic fatty liver disease

Ann Hepatol. 2020 Sep-Oct;19(5):458-465. doi: 10.1016/j.aohep.2019.11.010. Epub 2020 Jan 2.

Abstract

Currently, chronic liver diseases have conditioned morbidity and mortality, many of these with a metabolic, toxicologic, immunologic, viral, or other etiology. Thus, a transcription factor that has been of huge importance for biomedical research is NRF-2. The latter is considered a principal component of the antioxidant mechanism, and it has been acknowledged that it impairs the function of NRF-2 in many liver diseases and that it forms an essential part of the pathologic changes that occur in the liver to contain inflammation and damage. Within the investigations and experiments carried out, there are isolated drugs, many of them related to plants and natural extracts that possess antioxidant properties through the NRF-2 signaling pathway, or even involving the stimulation of the transcription target proteins of NRF-2. Notwithstanding all of these experimental findings, to date there is not sufficient clinical evidence to justify the use of NRF-2 in medical practice.

Keywords: Liver antioxidants; NRF-2; Non-alcoholic fatty liver disease and KEAP1; Oxidative stress; Steatohepatitis.

Publication types

  • Review

MeSH terms

  • Animals
  • Antioxidants / therapeutic use
  • Humans
  • Liver / drug effects
  • Liver / metabolism*
  • Liver / pathology
  • NF-E2-Related Factor 2 / metabolism*
  • NF-E2-Related Factor 2 / therapeutic use
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Non-alcoholic Fatty Liver Disease / pathology
  • Oxidative Stress* / drug effects
  • Signal Transduction

Substances

  • Antioxidants
  • NF-E2-Related Factor 2